

Amendment to the Claims:

Claims 1-4, 10, 16, 30, 36, 37 (Withdrawn)

Claims 5-9, 11-15, 17-19, 31-35, 38 (Canceled)

39. (currently amended) A transgenic mouse whose genome comprises a homozygous disruption in a gene encoding mCAR2~~mCAR~~ gene, wherein as a result of the disruption, the transgenic mouse lacks production of functional protein encoded by said gene and exhibits, relative to a wild-type mouse, impaired coordination or balance, a spleen abnormality, a thymus abnormality or a lymph node abnormality.
40. (previously presented) The transgenic mouse of claim 39, wherein the impaired coordination or balance comprises decreased performance in a rotarod test.
41. (previously presented) The transgenic mouse of claim 39, wherein the spleen abnormality comprises decreased spleen size.
42. (previously presented) The transgenic mouse of claim 39, wherein the spleen abnormality comprises reduced spleen weight.
43. (previously presented) The transgenic mouse of claim 39, wherein the spleen abnormality comprises reduced spleen to body weight ratio.
44. (previously presented) The transgenic mouse of claim 39, wherein the spleen abnormality comprises lymphoid depletion of the spleen.
45. (previously presented) The transgenic mouse of claim 39, wherein the thymus abnormality comprises reduced thymus size.
46. (previously presented) The transgenic mouse of claim 39, wherein the thymus abnormality comprises reduced thymus weight.
47. (previously presented) The transgenic mouse of claim 39, wherein the thymus abnormality comprises reduced thymus to body weight ratio.
48. (previously presented) The transgenic mouse of claim 39, wherein the thymus abnormality comprises lymphoid depletion in the thymus.
49. (previously presented) The transgenic mouse of claim 39, wherein the lymph node abnormality comprises lymphoid depletion.
50. (previously presented) The transgenic mouse of claim 39, wherein the lymph node abnormality comprises reduced lymph node size.

Claims 51-52 (Canceled).